Short review of immunotherapy toxicity

Short review of immunotherapy toxicity

Immune checkpoint inhibitors, such as CTLA-4 inhibitors (ipilimumab), PD-1 (nivolumab, pembrolizumab), and PDL1 inhibitors (atezolizumab, durvalumab) have become standard in the treatment of numerous malignant tumors. Immunotherapy blocks the body’s natural protective measures with immune checkpoin...

Full description

Bibliographic Details
Main Authors: Ivana Canjko, Luka Perić, Josipa Flam, Maja Kovač-Barić, Darko Kotromanović, Nora Pušeljić, Mirela Šambić-Penc
Format: Article
Language:English
Published: University Hospital for Tumors 2021-01-01
Series:Libri Oncologici
Subjects:
immunotherapy
immune checkpoint inhibitors
adverse events
Online Access:https://hrcak.srce.hr/file/389037

Internet

https://hrcak.srce.hr/file/389037

Similar Items